Picture of Biofrontera AG logo

B8F Biofrontera AG News Story

de flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

REG - Biofrontera AG - FDA completes Ameluz NDA mid-cycle review <Origin Href="QuoteRef">B8FGn.DE</Origin>

RNS Number : 0003N
Biofrontera AG
26 January 2016

FDA completes Biofrontera's Ameluz NDA mid-cycle review

Leverkusen, Germany, 26 January 2016 - Biofrontera (FSE/AIM: B8F), the biopharmaceutical company focusing on sun-induced skin cancer, has today announced recent progress on the ongoing approval process for Ameluz and BF-RhodoLED in the USA. FDA has now completed its mid-cycle review of the Ameluz NDA (new drug application). The review resulted in no additional requests for material nor were any additional review issues highlighted.

Ameluz is a prescription drug used in combination with Biofrontera's proprietary lamp, BF-RhodoLED, as a photodynamic therapy (PDT) to treat actinic keratosis. Ameluz is currently approved in the EU and Switzerland. With European sales continuously growing, an approval in the USA would create a significantly larger market opportunity for Biofrontera. The US market opportunity for Ameluz and BF-RhodoLED is particularly promising since PDT for actinic keratosis is a fully reimbursed Medicare procedure, which is not generally the case in Europe.

"The results of the mid-cycle review support our expectations. With this potential hurdle behind us, we do not anticipate any major delays and we look forward to FDA completing its review in the spring", commented Prof. Hermann Luebbert, CEO of Biofrontera."


Enquiries, please contact:

Biofrontera AG

Thomas Schaffer, Chief Financial Officer

+49 (0) 214 87 63 2 0



IR Germany: Brainwell Asset Solutions

Jrgen Benker

+49 (0) 152 08931514

Nomad and Broker: Shore Capital

Bidhi Bhoma / Toby Gibbs

+44(0) 20 7408 4090

IR UK: Seton Services

Toni Vallen

+44(0) 20 7729 0805

Financial PR: Gable Communications

John Bick / Justine James

+44(0) 20 7193 7463

+44 (0)7872 061007


Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos dermatological range of cosmetics. Belixos products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lbbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.


This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.

This information is provided by RNS
The company news service from the London Stock Exchange

Recent news on Biofrontera AG

See all news